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HDAC inhibition activates the 
apoptosome via Apaf1 upregulation 
in hepatocellular carcinoma
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Abstract 
Background: Histone deacetylation, a common hallmark in malignant tumors, strongly alters the transcription of 
genes involved in the control of proliferation, cell survival, differentiation and genetic stability. We have previously 
shown that HDAC1, HDAC2, and HDAC3 (HDAC1–3) genes encoding histone deacetylases 1–3 are upregulated in 
primary human hepatocellular carcinoma (HCC). The aim of this study was to characterize the functional effects of 
HDAC1–3 downregulation and to identify functionally important target genes of histone deacetylation in HCC.
Methods: Therefore, HCC cell lines were treated with the histone deacetylase inhibitor (HDACi) trichostatin A and by 
siRNA-knockdown of HDAC1–3. Differentially expressed mRNAs were identified after siRNA-knockdown of HDAC1–3 
using mRNA expression profiling. Findings were validated after siRNA-mediated silencing of HDAC1–3 using qRTPCR 
and Western blotting assays.
Results: mRNA profiling identified apoptotic protease-activating factor 1 (Apaf1) to be significantly upregulated after 
HDAC inhibition (HLE siRNA#1/siRNA#2 p < 0.05, HLF siRNA#1/siRNA#2 p < 0.05). As a component of the apoptosome, 
a caspase-activating complex, Apaf1 plays a central role in the mitochondrial caspase activation pathway of apopto-
sis. Using annexin V, a significant increase in apoptosis could also be shown in HLE (siRNA #1 p = 0.0034) and HLF after 
siRNA against HDAC1–3 (Fig. 3a, b). In parallel, caspase-9 activity was increased after siRNA-knockdown of HDAC1–3 
leading to enhanced apoptosis after HDAC inhibition (Fig. 3c, d).
Conclusions: The present data show that siRNA-knockdown of HDAC1–3 plays a major role in mediating apoptotic 
response to HDAC inhibitors through regulation of Apaf1.
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Background
Hepatocellular carcinoma (HCC) represents the fourth 
most common malignant tumor with more than 1 million 
persons affected per year worldwide [1, 2]. HCC is asso-
ciated with a very poor prognosis (http://www-dep.iarc.
fr/) [3, 4] and only limited treatment options are avail-
able. Therefore, new effective therapeutic strategies are 
urgently needed.
Currently, cancer development is regarded as an inter-
action of genetic, genomic and epigenetic alterations 
[5–9]. The histone modification, i.e. acetylation, of lysine 
residues is an important secondary modification respon-
sible for chromatin remodeling and is controlled by his-
tone acetyltransferases (HATs) and histone deacetylases 
(HDACs). The deacetylation of chromatin results in the 
formation of a higher order, i.e. condensation of chro-
matin, leading to the repression of transcription of many 
genes involved in multiple cellular functions. Notably, 
epigenetic modifications are reversible and can be tar-
geted by new drugs like DNA methyltransferase and 
HDAC inhibitor (HDACi), drugs that have shown effi-
cacy in clinical phase I/II studies (http://www.clinical-
trials.gov) [10]. HDACi are found to have an anti-cancer 
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We have previously shown that HDAC1–3 are upreg-
ulated in primary human HCC [13]. Therefore, we 
hypothesized that the altered expression of genes due 
to chromatin remodeling may play a fundamental role 
in hepatocarcinogenesis. We hence induced histone 
acetylation by HDACi or siRNA silencing of HDAC1–3 
to identify functionally important target genes. Upon 
increasing histone acetylation, the apoptotic protease-




Analysis was carried out based on the re-evaluation of 
pseudonymized tumor specimens of 23 patients with 
HCC treated at Hannover Medical School (MHH) and 
taken from the archive of the Institute of Pathology at 
the MHH (Germany) [13]. The local Ethics Commit-
tee (“Ethikkommission der Medizinischen Hochschule 
Hannover”, head: Prof. Dr. H.D. Tröger) approved the 
application to retrospectively use the samples in this 
study (left over from diagnostic procedures) that had 
been irreversibly unlinked from the source, render-
ing them anonymous, and thus exempting them from 
IRB review, waiving the consent requirement due to 
no legal or ethical concerns (Ethics Statement: No. 
2208–2014).
Cell culture, HDAC inhibition and transfection
HCC cell lines HLE [14] and HLF [14] (kindly provided 
by Professor Nam-Ho Huh, Department of Cell Biology, 
Graduate School of Medicine, Dentistry and Pharma-
ceutical Sciences, Okayama University, Okayama, Japan) 
were treated with trichostatin A (TSA) or transfected 
with siRNA against HDAC1–3 as previously described 
[13]. siRNA#1 and #2 are different mixtures of siRNAs 
against HDAC1, HDAC2 and HDAC3 provided by Qia-
gen, Hilden, Germany (siRNA#1  =  Hs_HDAC1_1, Hs_
HDAC2_3, Hs_HDAC3_10; siRNA#2  =  Hs_HDAC1_6, 
Hs_HDAC2_1, Hs_HDAC3_9).
Expression analyses
Microarray analyses were done as previously described 
with Whole Human Genome Oligo Microarray 
Kit  4 ×  44  k (Agilent) [13]. The array analysis was per-
formed by a paired t test of treated against untreated 
cells with a corrected (Benjamini–Hochberg) p value of 
0.1. The Agilent GeneSpring GX Data Analysis Software 
was used for bioinformatic analysis. mRNAs of interest 
were validated by qRTPCR as previously described [13] 
with Taqman Assay [Hs00559421_m1, amplicon spans 
exon 10 and 11 with a length of 112 bp (Applied Biosys-
tems)] and Western blot using antibody against Apaf1 
[#8723 Cell Signaling/NEB Danvers, MA, USA, Antibody 
ID: AB_10829610 from http://www.antibodyregistry.
org, used 1:1000, blocking with 3 % Slim Fast chocolate 
(Allpharm)].
Assays to determine apoptosis and caspase‑9 activity
To detect apoptotic cells, both adherent and floating 
cells were collected and washed twice with PBS. Cells 
were resuspended in 1× binding buffer (Becton–Dick-
inson) and stained with 5  µL annexinV-APC (Bec-
ton–Dickinson) and 5  µL 7-AAD (Becton–Dickinson) 
for 15 min in the dark. Samples were analyzed with the 
FACSCalibur flow cytometer (Becton–Dickinson). Data 
analysis was performed using CellQuest Pro software 
(Becton–Dickinson).
To detect viable cells, the activity of the mitochon-
drial dehydrogenase was determined using the Cell Pro-
liferation Reagent WST-1 in 96-well format (Roche, 
Mannheim, Germany). To determine caspase-9 activ-
ity, Caspase-Glo® 9 Assay (G8210, Promega) was used. 
Absorption was measured using the Synergy 2 Multi-
Mode Microplate Reader (BioTek).
Statistics
For statistical analysis, GraphPad Prism version 5.02 
for Windows was used. Each assay (except for microar-
rays) was performed three times in biologically inde-
pendent assays. 1-way ANOVA with Dunnett’s multiple 
comparison test was performed. Statistics are given as 
mean ±  standard deviation. Asterisks are related to the 
following p values in all experiments: *p  =  0.01–0.05 
significant, **p  =  0.001–0.01 very significant, and 
***p < 0.001 extremely significant.
Results
As recently published by Buurman et al. [13], HDAC1–3 
are upregulated in human primary HCC. To character-
ize the functional effects of deregulated HDAC1–3, HCC 
cell lines HLE, HLF, HepG2 and Huh-7 were treated with 
HDACi TSA. To rule out such unspecific and toxic side 
effects of HDACs by inhibitors like TSA in the two cell 
lines HLE and HLF, siRNA-knockdown of combined 
HDAC1–3 was performed.
Aiming to determine the influence of increased his-
tone acetylation on mRNA expression in HCC, we inves-
tigated global mRNA expression by microarray analyses 
in HCC cell lines treated with specific siRNA against 
HDAC1–3 for 48 h.
This led to significant differences in gene expression 
between treated and untreated cells. Apaf1 showed the 
most pronounced differential expression levels compared 
to untreated cells. Since Apaf1 is a central protein of the 
intrinsic apoptotic pathway and the core molecule in the 
Page 3 of 6Buurman et al. Eur J Med Res  (2016) 21:26 
formation of the apoptosome, a caspase-activating com-
plex, this gene was investigated further.
As shown in Fig.  1a, b, qRTPCR confirmed the result 
of the array analyses and showed a systematic increase in 
Apaf1 expression after siRNA treatment against HDAC1–
3 (HLE siRNA#1/siRNA#2 p  <  0,05, HLF siRNA#1/
siRNA#2 p  <  0,05). HLE and HLF showed increased 
Apaf1 expression using siRNA#1 about 118/93  % in 
comparison to the controls and using siRNA#2 about 
81/70  %. Furthermore, expression of Apaf1 was ana-
lyzed by Western blot analyses (Fig. 1c) in HLE and HLF 
cell lines after siRNA treatment against HDAC1–3. An 
increase in Apaf1 protein expression was seen after his-
tone deacetylation inhibition, substantiating also the 
result of the microarray analyses.
Moreover, qRTPCR was performed focusing on Apaf1 
in the four HCC cell lines HLE, HLF, HepG2 and Huh-7 
which were incubated with HDACi TSA for 12 h to vali-
date the results from previous experiments. As shown 
in Fig.  2, qRTPCR confirmed the result of siRNA treat-
ment against HDAC1–3 and showed an increase in Apaf1 
expression after HDACi treatment. HLE, Huh7 and 
HepG2 showed an increased Apaf1 expression with a sig-
nificance of p = 0.01–0.05 (HLE 68 %, HLF 59 %, Huh7 
173 %, HepG2 = 124 % increase).
To investigate the effect of histone acetylation and 
upregulation of Apaf1 on apoptosis induction, apoptosis 
and proliferation were measured 48 h after siRNA trans-
fection against HDAC1–3. In a previous study [13], it 
could be shown that acetylation was increased by more 
than 50 % and a significant increase in caspase 3/7 activ-
ity of more than 50 % than in controls. Using annexin V, 
a significant increase in apoptosis could also be shown 
in HLE [siRNA#1 80 %, siRNA#2 20 % increase (siRNA 
#1 p = 0.0034)] and HLF (siRNA#1 38 %, siRNA#2 28 % 
increase) after siRNA against HDAC1–3 (Fig.  3a, b). In 
parallel, both HCC cell lines showed an increase of cas-
pase 9 activity after 48 h compared with controls (Fig. 3c, 
d). The increase was between 26 and 76 % with exception 
of siRNA#2 in HLE.
To confirm the clinical relevance of the deregulation of 
Apaf1, 23 primary HCC were investigated using qRTPCR. 
Fig. 1 Expression of Apaf1 after siRNA transfection against HDAC1–3 in HLE and HLF. 48 h after transfection of siRNA against HDAC1–3, the HCC 
cell lines a HLE and b HLF showed a significant increased expression of Apaf1 measured by qRTPCR. c Western blot analysis of Apaf1 after siRNA 
showed a significant increase in Apaf1 expression compared with controls. Values are mean ± SEM, n = 3. ***p < 0.001, **p < 0.01, *p ≤ 0.05, ANOVA 
plus Dunnett’s posttest
Page 4 of 6Buurman et al. Eur J Med Res  (2016) 21:26 
Compared to a human reference, Apaf1 expression was 
reduced in more than half of the primary HCC (Fig. 4).
Discussion
Histone deacetylation represents an important epige-
netic modification in cancer development and is respon-
sible for condensation of chromatin and transcriptional 
silencing in the respective genomic regions. In a previ-
ous study, we have shown that HDAC1–3 are consistently 
upregulated in HCC [13].
Transcriptional repressors such as class I HDACs are 
receiving growing attention as potential therapeutic tar-
gets in human malignancies [15]. Several HDACi have 
been identified that drive tumor cells into growth arrest, 
differentiation, and apoptotic cell death [16]. Meanwhile 
several HDAC-specific inhibitors are being tested in pre-
clinical and clinical trials [15].
In a previous study, we have shown that treatment of 
HCC cell lines with the HDACi TSA or with specific 
Fig. 2 Expression of Apaf1 after 12-h treatment with the HDACi TSA. 
Expression of Apaf1 after 12-h treatment with the HDACi TSA in the 
HCC cell lines HLE, HLF, Huh7 and HepG2 measured by qRTPCR. After 
treatment, Apaf1 showed an increased expression compared with 
controls. Values are mean ± SEM, n = 3, *p ≤ 0.05, ANOVA plus Dun-
nett’s posttest
Fig. 3 Apoptosis after siRNA transfection against HDAC1–3. Apoptosis measured by flow cytometry using annexin V staining in HLE a and HLF b is 
increased in both cell lines. Caspase-9 activity in the HCC cell lines c HLE and d HLF normalized to cell count after 48 h showed a significant increase 
in caspase-9 activity in both cell lines compared with controls. Values are mean ± SEM, n = 3. **p < 0.01, *p = <0.05, ANOVA plus Dunnett’s posttest
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siRNA against HDAC1, 2 and 3 led to increased histone 
acetylation [13]. Using gene expression profiling after 
specific downregulation of HDAC1, 2 and 3 in HCC 
cell lines HLE and HLF, we observed an upregulation of 
Apaf1. Apaf1 showed the most pronounced differential 
expression levels compared to untreated cells. This gene 
plays a central role in the mitochondrial caspase activa-
tion pathway of apoptosis. Indeed, after siRNA treatment 
against HDAC1–3, Apaf1 expression was increased, cas-
pase-9 was activated and apoptosis induced significantly 
[13].
Human cancers are characterized by an imbalance 
of regulatory mechanisms controlling different cellular 
pathways, including apoptosis. Apaf1 and the cysteine 
proteases known as caspases are central proteins of the 
intrinsic apoptotic pathway. This pathway of apoptosis is 
activated by death stimuli that induce the release of pro- 
apoptotic factors such as cytochrome c from mitochon-
dria into the cytosol and trigger the subsequent formation 
of the apoptosome, an oligomeric protein complex con-
sisting of Apaf1, procaspase-9, cytochrome c, and deoxy-
adenosine triphosphate (ATP) [17]. Mature caspase-9 
activates downstream caspases, such as caspase-3, result-
ing in the controlled demise of the cell [18]. It is known 
that the histone acetylation and deacetylation in the 
retina are epigenetic phenomena that have an influence 
on the transcriptional repression of Apaf1 [19]. Further-
more, Tan et al. [20] could show that TSA restores Apaf1 
function in chemoresistant ovarian cancer cells. It is also 
known that Apaf1 is inactivated in metastatic melano-
mas [21]. Interestingly, TSA treatment did not result in 
increased Apaf1 levels in melanoma cells, suggesting that 
HDAC inhibitor effects on apoptotic factors may be cell-
type-specific [22]. Moreover, it is known that HDACi can 
induce p53 acetylation which leads to the transcriptional 
upregulation of Apaf1 [23]. Moreover, Hanigan et al. [24] 
could show that HDAC2 regulates Apaf1 mediating the 
apoptotic response to HDAC inhibitors.
Conclusions
Our studies demonstrate that HDAC1–3 play a major 
role in mediating apoptotic response to HDAC inhibitors 
through direct regulation of Apaf1 in HCC.
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